Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine and composition for treating cerebral ischemic diseases

A technology for cerebral ischemic disease and composition, which is applied in the field of genipin-1-β-D-gentiobiglycoside and its composition, can solve problems such as unreported use, and achieves improvement of survival rate and reduction of behavior grading, the effect of reducing the area

Active Publication Date: 2017-01-11
樊向德 +1
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no report about the use of genipin-1-β-D-gentiobioside and its composition in the preparation of medicines for treating cerebral ischemic diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine and composition for treating cerebral ischemic diseases
  • Medicine and composition for treating cerebral ischemic diseases
  • Medicine and composition for treating cerebral ischemic diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039]Take 500g of gardenia, crush it, soak it with 4L of 30% (V / V) ethanol for 1 hour, reflux extraction for 2 hours, then reflux extraction with 3L of the same concentration of ethanol for 1 hour, filter, combine the filtrates, and recover ethanol under reduced pressure (-9Pa , 60°C) to obtain the extract; load the extract on AB-8 macroporous resin, elute with 2 times column volume of water, load the eluate on ADS-7 macroporous resin, and use 2 times column volume, Concentration is the ethanol elution of 30% (V / V), eluent decompression recovers ethanol and then puts sample on ADS-7 macroporous resin, continues to be 50% (V / V) ethanol with 3 times of column volumes, concentration ethanol elution, the eluate was recovered under reduced pressure to recover ethanol, continued to concentrate under reduced pressure, and the concentrated solution was treated with absolute ethanol to obtain the monomer component genipin-1-β-D-gentiobioside.

Embodiment 2

[0041] Take 1000g of gardenia, crush it, soak it with 8L 70% (V / V) ethanol for 1 hour, reflux extraction for 2 hours, then extract it with 7L of the same concentration of ethanol for 1 hour, filter, combine the filtrates, and recover ethanol under reduced pressure (-9Pa, 60 ℃), to obtain the extract; the extract was loaded on the D101 macroporous resin, and eluted with 3 times the column volume of water, and the eluate was loaded on the S-8 macroporous resin, with 3 times the column volume and a concentration of 20 % (V / V) ethanol for elution, the eluent was decompressed to recover ethanol and then loaded on the S-8 macroporous resin, and continued to elute with 2 times the column volume and a concentration of 40% (V / V) ethanol , ethanol is recovered from the eluate under reduced pressure, and the concentration under reduced pressure is continued, and the concentrated solution is treated with absolute ethanol to obtain the monomer component genipin-1-β-D-gentiobioside.

Embodiment 3

[0043] Take 600g of Gardenia jasminoides, crush them, immerse and extract in 5.4L room temperature water for 6 hours, then immerse and extract in 4.2L water for 4 hours, stir during the immersion process, filter, and combine the filtrates to obtain the extract, and put the extract in AB-8 Load the sample on the macroporous resin, elute with 2 times the column volume of water, load the eluate on the S-8 macroporous resin, elute with 2 times the column volume and 20% (V / V) ethanol, and elute After recovering ethanol under reduced pressure, load the sample on S-8 macroporous resin, continue to elute with ethanol with 2 times the column volume and a concentration of 40% (V / V), recover ethanol under reduced pressure from the eluent, and continue to concentrate under reduced pressure , the concentrated solution is treated with absolute ethanol to obtain the monomer component genipin-1-β-D-gentiobioside.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of traditional Chinese medicines, and in particular relates to a novel application of genipin-1-[beta]-D-gentiobioside and a composition thereof. The genipin-1-[beta]-D-gentiobioside and the composition thereof can take a significant effect on treating a model rat with cerebral ischemia-reperfusion injury, obviously reduce behavioral scores of the model rat, significantly diminish the area of a brain slice infarction area of the model rat and reduce TNF-[alpha] and 1L-6 contents in serum of the model rat; an obvious therapeutic effect can be taken on a Bend.3 cell ischemic injury model which is cultured in vitro, the survival rate of injured cells can be significantly improved and a cell death-protection rate is positively related to a drug concentration; and the contents of tumor necrosis factors (TNF-[alpha]) and interleukin 6 (1L-6) in supernatant liquid of a Bend.3 cell hypoxia / reoxygenation model which is cultured in vitro can be obviously reduced. Moreover, based upon an acute toxicity test in mice and a long-term toxicity in rats, it indicates that the genipin-1-[beta]-D-gentiobioside and the composition thereof are free from toxic and side reactions.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicine, and in particular relates to the new application of genipin-1-beta-D-gentiobioside and its composition. Background technique [0002] Cerebral ischemic disease refers to the ischemia and hypoxia in the corresponding area caused by the blood supply disorder of the brain tissue, which leads to a series of pathophysiological and biochemical changes in the brain tissue, and finally causes the damage of the brain tissue and the loss of the function of the corresponding tissue area. Cerebral ischemic disease is a frequently-occurring and common disease of the nervous system, with high morbidity, high mortality, and high disability rate, which seriously affects the quality of life of patients and brings heavy economic and spiritual burdens to families and society. burden. [0003] At present, the treatment methods for cerebral ischemic diseases mainly include: recanalization of blood vessels...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P9/10
Inventor 樊向德陈鸣珍
Owner 樊向德
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com